18 July, 2017
About 66,852 shares traded. During the same period previous year, the business posted ($0.09) earnings per share. Mgp Ingredients Inc New now has $871.92M valuation. The stock declined 0.67% or $0.24 reaching $35.49 on the news. About 4.97M shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 3.00% since July 14, 2016 and is uptrending. It has outperformed by 85.82% the S&P500.
A number of other analysts also recently commented on the company. Therefore 50% are positive. Enanta Pharmaceuticals Inc has $45 highest and $16 lowest target. JMP Securities upgraded Enanta Pharmaceuticals from a market perform rating to an outperform rating and set a $40.00 price target for the company in a research note on Tuesday, July 11th. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Monday, July 3rd. BidaskClub lowered shares of Enanta Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday. JMP Securities downgraded Enanta Pharmaceuticals Inc (NASDAQ:ENTA) on Thursday, April 28 to "Market Perform" rating. The stock of Target Corporation (NYSE:TGT) earned "Strong-Buy" rating by Vetr on Tuesday, September 8.
Investors sentiment decreased to 1.47 in Q4 2016. Its down 0.06, from 1.53 in 2016Q3. 20 funds opened positions while 43 raised stakes. Bamco Inc New York accumulated 17,000 shares or 0% of the stock. Tower Research Capital LLC (trc) reduced its holdings by selling 328 shares a decrease of 47.4% from 12/31/2016 to 03/31/2017. Institutional investors own 67.32% of the company's stock. Diker Mgmt accumulated 35,600 shares.
06/17/2014 - Macquarie began new coverage on Enanta Pharmaceuticals, Inc. giving the company a " rating. Krensavage Asset Management Llc bought 55,978 shares as the company's stock rose 11.35% with the market. Hays Advisory Ltd Liability Company holds 0.87% or 116,939 shares. 13,306 are held by Aperio Group Inc Ltd Liability. New York State Common Retirement Fund holds 42,874 shares or 0% of its portfolio. Manatuck Hill Prtn Limited has invested 3.93% of its portfolio in MGP Ingredients Inc (NASDAQ:MGPI).
Since May 1, 2017, it had 0 insider purchases, and 1 insider sale for $46,235 activity. 281 shares were bought by Glaser Stephen J, worth $13,940 on Monday, March 13. Fincl Bank Of America De, North Carolina-based fund reported 19,045 shares. DYKSTRA DAVID E sold $296,235 worth of stock or 5,353 shares. November 22 investment analysts at Baird made no change to the stock rating of "Neutral" and lowered the price expectation from $41.00 to $27.00. Therefore 18% are positive.
08/15/2014 - Enanta Pharmaceuticals, Inc. had its " rating reiterated by analysts at Credit Suisse. The firm has "Buy" rating given on Friday, August 7 by Zacks. The stock has "Buy" rating by TheStreet on Saturday, August 8.
Investors sentiment decreased to 1.16 in Q4 2016. Its up 0.11, from 1.64 in 2016Q3. Airain Limited holds 0.02% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 6,325 shares. 23 funds opened positions while 49 raised stakes. California Pub Employees Retirement Sys reported 13,700 shares or 0% of all its holdings. Acadian Asset Lc reported 86,196 shares or 0% of all its holdings.
The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a huge mover today! Ubs Oconnor Limited Co holds 0% or 1.10 million shares. State Of Tennessee Treasury Department reported 10,446 shares. 7,958 were reported by Sg Americas Securities Limited Liability Corp. Granahan Inv Mgmt Ma reported 496,025 shares stake. It improved, as 6 investors sold Synacor Inc shares while 6 reduced holdings. New Jersey Better Educational Savings Tru reported 140,000 shares. PNC Financial Services Group Inc. owned 0.36% of Enanta Pharmaceuticals worth $2,123,000 at the end of the most recent quarter. Clearbridge Invs Limited Liability Com owns 3,806 shares or 0% of their USA portfolio. Vanguard Incorporated holds 16.53 million shares. The company's quarterly revenue was down 30.8% on a year-over-year basis. It has outperformed by 24.21% the S&P500. The Company's research and development programs are focused on three disease targets: non-alcoholic steatohepatitis / primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). Enanta Pharmaceuticals, Inc. The stock's market cap is $711.22 million. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases.
